Received: 27 November 2020
Revised: 11 February 2021
Accepted: 12 February 2021
First Online: 20 February 2021
Compliance with ethical standards
: Markus Reindl was supported by research grants from Euroimmun and Roche and is supported by a research grant from the Austrian Science Fund (FWF projects P32699). The University Hospital and Medical University of Innsbruck (Austria; employer of Dr. Reindl) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). Romain Marignier reports personal fees and non-financial support from Viela Bio, non-financial support from Merck, non-financial support from Biogen, personal fees and non-financial support from Roche, personal fees from UCB, outside the submitted work. S. Ferrari received a support for congress attendance by Shire, Euroimmun, and Merck. Sara Mariotto received support for attending scientific meetings by Merck and Euroimmun and received speaker honoraria from Biogen. The other authors have no relevant financial or non-financial interests to disclose.
: The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.